Document is current

Article History

Received: 4 November 2024

Accepted: 11 February 2025

First Online: 20 February 2025

Competing interests

: MB reports travel support from Eli Lilly. GG reports fees for advisory role from Gilead, Seagen, Menarini, personal fees as an invited speaker from Eli Lilly, Novartis, MSD, travel support Gilead, Eli Lilly, Pfizer, Novartis, Daiichi Sankyo, AMGEN, AstraZeneca. SG reports honoraria and consulting fees from Pfizer, Lilly, Astra Zeneca and Gilead. CB reports travel expenses and fees for oral presentations and boards from Daiichi-Sankyo, Astra-zeneca, Seagen. FM reports personal fees from Roche, Novartis, Pfizer, Seagen, Menarini, MSD, Gilead, Astrazeneca. CZ reports travel support from Eli Lilly, Sanofi, Gilead. FG reports travel support from Eli Lilly, Gilead, Novartis; honoraria for lectures: AstraZeneca, Eli Lilly, Gilead. WJ reports grants, personal fees and non-financial support from Astra Zeneca, personal fees and non-financial support from Eisai, Novartis, Roche, Pfizer, Eli Lilly, Chugai and Gilead, personal fees from MSD, BMS and Seagen, grants and personal fees from Daiichi Sankyo, outside the submitted work. MVD reports personal fees for consultancy/advisory role from: Eli Lilly, Pfizer, Novartis, Seagen, Gilead, MSD, Exact Sciences, AstraZeneca, Roche, Daiichi Sankyo, Roche. AD reports honoraria for advisory board participation from Novocure, Servier Pharmaceuticals; travel grant from Servier Pharmaceuticals. VG reports personal fees for advisory board membership for AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, MSD, Novartis, Pfizer, Olema Oncology, Pierre Fabre, Roche, Menarini Stemline, personal fees as an invited speaker for AstraZeneca, Daiichi Sankyo, Eli Lilly, Exact Sciences, Gilead, GSK, Novartis, Roche, Zentiva, Menarini Stemline, personal fees for expert testimony for Eli Lilly. The other authors declare no conflicts of interest.